Is BioCryst Pharmaceuticals, Inc. (BCRX) a Buy? The Stock Formed Bullish Descending Triangle

December 8, 2017 - By Henry Gaston

Investors sentiment increased to 1.68 in 2017 Q2. Its up 0.18, from 1.5 in 2017Q1. It is positive, as 15 investors sold BioCryst Pharmaceuticals, Inc. shares while 19 reduced holdings. 18 funds opened positions while 39 raised stakes. 66.24 million shares or 8.58% more from 61.01 million shares in 2017Q1 were reported.
Moreover, Acuta Prns Lc has 0.26% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 168,685 shares. Legal General Plc reported 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Fmr Ltd accumulated 3.12M shares. Da Davidson & stated it has 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Bnp Paribas Arbitrage holds 0% or 8,854 shares in its portfolio. Aqr Capital Mngmt Ltd Liability Corp invested in 0% or 54,322 shares. Fin Architects accumulated 30 shares. Emory University reported 287,550 shares. Moreover, Comerica Bancshares has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). State Street Corp stated it has 3.91M shares or 0% of all its holdings. Jpmorgan Chase Communication invested in 0% or 244,613 shares. Oberweis Asset Management accumulated 17,100 shares or 0.03% of the stock. Fincl Bank Of Montreal Can invested in 1,000 shares. 46,149 are owned by Nationwide Fund Advsr. New York-based Sg Americas Secs Lc has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

The stock of BioCryst Pharmaceuticals, Inc. (BCRX) formed a descending triangle with $4.75 target or 4.00 % above today’s $4.57 share price. The 7 months triangle pattern indicates low risk for the $449.71M company. If the $4.75 price target is reached, the company will be worth $17.99M more.
The descending triangle is in our view more reliable than the ascending one. The descending triangle pattern has break even failure rate for up and down breakouts of 7% and 16%, respectively. The average rise and decline is 47% and 16%. The throwback or so called pullback rates are: 37% and 54%. The stocks meeting their targets is high for this type of breakout: 84% and 54% percent.

The stock decreased 0.44% or $0.02 during the last trading session, reaching $4.57. About 663,349 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since December 8, 2016 and is uptrending. It has outperformed by 58.38% the S&P500.

Analysts await BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings on February, 26. They expect $-0.15 earnings per share, down 150.00 % or $0.09 from last year’s $-0.06 per share. After $-0.18 actual earnings per share reported by BioCryst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -16.67 % EPS growth.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Among 13 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. BioCryst Pharmaceuticals had 31 analyst reports since August 7, 2015 according to SRatingsIntel. FBR Capital maintained the shares of BCRX in report on Tuesday, February 9 with “Outperform” rating. JMP Securities downgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Thursday, August 4 to “Market Perform” rating. On Wednesday, September 9 the stock rating was initiated by Jefferies with “Hold”. The rating was maintained by Noble Financial with “Buy” on Friday, May 26. The stock has “Buy” rating by H.C. Wainwright on Wednesday, November 8. Bank of America downgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Friday, October 9 to “Neutral” rating. Piperjaffray upgraded the shares of BCRX in report on Friday, August 12 to “Overweight” rating. H.C. Wainwright maintained the shares of BCRX in report on Friday, May 26 with “Buy” rating. The rating was upgraded by PiperJaffray on Friday, August 12 to “Overweight”. JMP Securities upgraded the shares of BCRX in report on Friday, December 16 to “Market Outperform” rating.

More news for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were recently published by:, which released: “Biotech Stock Performance Review — BioCryst Pharma, Celgene, Exelixis, and Geron” on November 21, 2017.‘s article titled: “BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q3 2017 Results …” and published on November 07, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.